Tyra Biosciences Inc
TYRAHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:14 AM ET
19.41-0.36 (-1.80%)
2026-11-13 13:53 CET
Market cap
$1.34B
Revenue, TTM
0.00 USD m
Net income, TTM
-169.82 USD m
Free cash flow, TTM
-119.78 USD m
EPS diluted, TTM
-2.63
Price
TYRA against its 20, 50 and 200-day averagesPatternshover a marker to name it
52.3% under the 52-week high of 40.65 on 1 Apr 2026. 52-week low 14.67 on 13 Nov 2025. Last 15 sessions, 18.5% high to low
Volume 0.02× normal · the line is the 50-bar volume average
Setup. RS line 28
CANSLIM 2 of 6 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 0 of 4 — fails: EPS Growth Qtr Over Qtr: High (>25%); EPS Growth This Year: High (>25%); EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15% — not on the tape: Net Profit Margin: High (>20%); P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: Institutional Transactions: Over +10%; 200-Day Simple Moving Average: Price above SMA200
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
TYRA52-week range, 18% of the way up
14.6740.65
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. Its proprietary in-house discovery platform, SNAP, enables the rapid and precise refinement of structural design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA is developing a pipeline of selective inhibitors of the Fibroblast Growth Factor Receptor (FGFR) family members, which are altered in approximately 7% of all cancers. The company was founded by Daniel Bensen and Todd Harris on August 2, 2018 and is headquartered in Carlsbad, CA.
| Index | RUT |
|---|---|
| Employees | 87 |
| IPO | Sep 15, 2021 |
| Beta | 0.68 |
| ATR, 14d | 1.14 |
| Rel volume | 0.02 |
| Short float | 18.71% |
| Insider own | 23.30% |
| Inst own | 85.84% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $1.34B |
| Enterprise Value | 645.70M |
| Income | -169.82M |
| Sales | 0.00M |
| Book / share | 10.04 |
| Cash / share | 10.14 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 87 |
| IPO | Sep 15, 2021 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | - |
| Price / book | 1.93 |
| Price / cash | 1.91 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | - |
| Quick Ratio | 23.93 |
| Current Ratio | 23.93 |
| Debt / equity | 0.01 |
| Long-term debt / equity | 0.01 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -2.63 |
|---|---|
| Earnings next year | -2.97 |
| Earnings next quarter | -0.72 |
| Earnings this year | -36.44% |
| Earnings next year | -8.45% |
| Earnings growth, 5 years | -17.43% |
| Past earnings growth | -15.07% -55.76% |
| Past sales growth | - - |
| Earnings vs last year | -40.04% |
| Sales vs last year | - |
| Earnings vs last quarter | -47.82% |
| Sales vs last quarter | - |
| Earnings | Nov 10 BMO |
| Surprise | -10.66% - |
Ownership
| Insiders own | 23.30% |
|---|---|
| Insider trades | 0.01% |
| Institutions own | 85.84% |
| Institution trades | 6.84% |
| Return on assets | -32.99% |
| Return on equity | -34.89% |
| Return on capital | -24.34% |
| Gross Margin | - |
| Operating margin | - |
| Profit Margin | - |
| 20-day average | -7.06% |
| 50-day average | -10.71% |
| 200-day average | -34.00% |
Technical
| Shares out | 68.98M |
|---|---|
| Shares floating | 52.91M |
| Short / float | 18.71% |
| Short ratio | 11.83 |
| Short interest | 9.90M |
| 52-week high | 40.65 -52.3% |
| 52-week low | 14.67 +32.3% |
| Volatility | 6.99% 5.27% |
| Average range | 1.14 |
| Strength index | 38.94 |
| Market sensitivity | 0.68 |
| Relative volume | 0.02 |
| Avg Volume | 836.96K |
| Volume | 664 |
Performance
| Perf Week | -8.23% |
|---|---|
| Perf Month | 1.94% |
| Perf Quarter | -25.97% |
| Perf Half Y | -47.60% |
| Perf YTD | -26.17% |
| Perf Year | 24.50% |
| Perf 3Y | 66.04% |
| Perf 5Y | -29.60% |
| Perf 10Y | - |
| Recommendation | 1.23 |
| Target Price | 45.78 |
| Prev Close | 19.76 |
| Price | 19.41 |
| Change % | -1.80% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 19, 2026 | Initiated | Wolfe Research | Peer Perform | ||
| Apr 15, 2026 | Initiated | Guggenheim | Buy | $54 | +178.2% |
| Apr 06, 2026 | Initiated | Canaccord Genuity | Buy | $50 | +157.6% |
| Feb 24, 2026 | Initiated | Cantor Fitzgerald | Overweight | ||
| Feb 10, 2026 | Initiated | William Blair | Outperform | ||
| Jan 28, 2026 | Initiated | Barclays | Overweight | $59 | +204.0% |
| Sep 03, 2025 | Initiated | Raymond James | Strong Buy | $35 | +80.3% |
| May 21, 2025 | Resumed | Piper Sandler | Overweight | $33 | +70.0% |
| Jan 07, 2025 | Initiated | UBS | Buy | $28 | +44.3% |
| Oct 18, 2024 | Upgrade | BofA Securities | Neutral → Buy | $22 → $31 | +59.7% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| BBIO | BridgeBio Pharma Inc | 15.37B |
| BMRN | Biomarin Pharmaceutical Inc | 10.98B |
| ASND | Ascendis Pharma A/S | 17.67B |
| RLAY | Relay Therapeutics Inc | 4.00B |
| URGN | UroGen Pharma Ltd | 1.30B |
| CGON | Cg Oncology Inc | 6.41B |
| INCY | Incyte Corp | 24.81B |
| ELVN | Enliven Therapeutics Inc | 3.56B |
| TNGX | Tango Therapeutics Inc | 4.21B |
| JNJ | Johnson & Johnson | 685.40B |
Insider trading
latest 14 of 26| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Verjee Rehan | Director | Sep 09 '26 | Buy | 20.58 | 972 | 20,000 | 972 | Sep 11 04:30 PM |
| NEXTECH VI ONCOLOGY SCSP | Shareholder | Jun 26 '26 | Proposed Sale | 30.94 | 308,379 | 9,541,246 | Jun 26 04:59 PM | |
| NEXTECH VI ONCOLOGY SCSP | Shareholder | Jun 01 '26 | Proposed Sale | 33.41 | 300,000 | 10,023,000 | Jun 01 04:16 PM | |
| Daniel Bensen | Officer | May 12 '26 | Proposed Sale | 34.25 | 8,000 | 274,000 | May 12 05:33 PM | |
| Daniel Bensen | Officer | Apr 13 '26 | Proposed Sale | 35.62 | 8,000 | 285,000 | Apr 13 04:44 PM | |
| KAPLAN GILLA | Director | Mar 25 '26 | Option Exercise | 2.25 | 14,295 | 32,164 | 42,526 | Mar 27 04:44 PM |
| KAPLAN GILLA | Director | Mar 25 '26 | Sale | 36.97 | 14,295 | 528,506 | 28,231 | Mar 27 04:44 PM |
| GILLA KAPLAN | Director | Mar 26 '26 | Proposed Sale | 37.75 | 53,172 | 2,007,153 | Mar 26 04:04 PM | |
| GILLA KAPLAN | Director | Mar 25 '26 | Proposed Sale | 36.97 | 14,295 | 528,506 | Mar 25 05:36 PM | |
| Daniel Bensen | Officer | Mar 12 '26 | Proposed Sale | 35.38 | 8,000 | 283,000 | Mar 12 05:42 PM | |
| Bensen Daniel | Chief Discovery Officer | Feb 12 '26 | Sale | 32.87 | 8,000 | 262,965 | 146,981 | Feb 13 04:30 PM |
| Daniel Bensen | Officer | Feb 12 '26 | Proposed Sale | 32.75 | 8,000 | 262,000 | Feb 12 04:52 PM | |
| Bensen Daniel | Chief Discovery Officer | Jan 12 '26 | Sale | 28.52 | 8,000 | 228,186 | 154,981 | Jan 20 04:30 PM |
| Daniel Bensen | Officer | Jan 12 '26 | Proposed Sale | 29.00 | 8,000 | 232,000 | Jan 12 05:38 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.44B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.64B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
News
latest 14 of 200- Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights (PR Newswire) -5.83%
- Tyra Biosciences to Participate in Upcoming Investor Conferences (PR Newswire)
- Raymond James Updates Healthcare Top Picks for October (Investing.com)
- Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (PR Newswire) +13.80%
- Tyra disappoints investors with bladder cancer data (BioPharma Dive) -17.66%
- Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress (Barrons.com)
- Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data (InvestorsHub)
- Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib (PR Newswire)
- Tyra Biosciences to Present at the Cantor Global Healthcare Conference (PR Newswire) -6.70%
- TYRA Stock Heads For Best Day In Nearly 10 Months Sets Date For Key Phase 2 Bladder Cancer Drug Readout (Stocktwits) +15.25%
- Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026 (PR Newswire)
- Tyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights (PR Newswire) -20.97%
- TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY (PR Newswire)
- Tyra Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights (PR Newswire)
Quarterly earnings
2026Q3 EPS -0.740 missed -0.669, from -0.500 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-10 08:30 | -0.740 | -0.669 | -0.740 | 0.00 | 0.00 | EPS +10.7% · sales - | vs 2025Q3, year-ago quarter · EPS +48.0% · sales - | 15 EPS · 9 sales | Open -1.35% vs SPY -0.63%. Close -5.83% vs SPY -0.37% |
| 2026Q2ended 2026-06-30 | 2026-08-04 16:30 | -0.690 | -0.650 | -0.690 | 0.00 | 0.00 | EPS +6.2% · sales - | vs 2025Q2, year-ago quarter · EPS +46.8% · sales - | 15 EPS · 9 sales | Open -10.85% vs SPY +0.59%. Close -20.97% vs SPY -0.20% |
| 2026Q1ended 2026-03-31 | 2026-05-13 08:30 | -0.640 | -0.588 | -0.637 | 0.00 | 0.00 | EPS +8.8% · sales - | vs 2025Q1, year-ago quarter · EPS +36.2% · sales - | 14 EPS · 9 sales | Open 0.00% vs SPY +0.04%. Close +3.79% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-02 16:30 | -0.570 | -0.532 | -0.566 | 0.00 | 0.00 | EPS +7.2% · sales - | vs 2024Q4, year-ago quarter · EPS +32.6% · sales - | 11 EPS · 8 sales | Open -3.44% vs SPY -1.65%. Close +1.51% vs SPY -0.88% |
| 2025Q3ended 2025-09-30 | 2025-11-05 16:30 | -0.500 | -0.498 | -0.501 | 0.00 | 0.00 | EPS +0.5% · sales - | vs 2024Q3, year-ago quarter · EPS +22.0% · sales - | 8 EPS · 4 sales | Open -0.61% vs SPY -0.16%. Close -3.64% vs SPY -1.07% |
| 2025Q2ended 2025-06-30 | 2025-08-14 16:30 | -0.470 | -0.529 | -0.472 | 0.00 | 0.00 | EPS -11.2% · sales - | vs 2024Q2, year-ago quarter · EPS +46.9% · sales - | 8 EPS · 5 sales | Open +5.14% vs SPY +0.16%. Close +0.28% vs SPY -0.23% |
| 2025Q1ended 2025-03-31 | 2025-05-08 16:30 | -0.470 | -0.486 | -0.474 | 0.00 | 0.00 | EPS -3.3% · sales - | vs 2024Q1, year-ago quarter · EPS +34.3% · sales - | 6 EPS · 3 sales | Open -0.30% vs SPY +0.25%. Close +0.20% vs SPY -0.13% |
| 2024Q4ended 2024-12-31 | 2025-03-27 16:30 | -0.430 | -0.474 | -0.433 | 0.00 | 0.00 | EPS -9.2% · sales - | vs 2023Q4, year-ago quarter · EPS -18.9% · sales - | 7 EPS · 3 sales | Open +8.70% vs SPY -0.27%. Close +1.14% vs SPY -2.01% |
| 2024Q3ended 2024-09-30 | 2024-11-07 16:30 | -0.410 | -0.399 | -0.408 | 0.00 | 0.00 | EPS +2.8% · sales - | vs 2023Q3, year-ago quarter · EPS -16.3% · sales - | 7 EPS · 4 sales | Open -2.68% vs SPY +0.09%. Close -6.06% vs SPY +0.43% |
| 2024Q2ended 2024-06-30 | 2024-08-07 16:30 | -0.320 | -0.408 | -0.319 | 0.00 | 0.00 | EPS -21.6% · sales - | vs 2023Q2, year-ago quarter · EPS +3.2% · sales - | 6 EPS · 3 sales | Open +3.18% vs SPY +1.01%. Close +4.31% vs SPY +2.31% |
| 2024Q1ended 2024-03-31 | 2024-05-09 16:30 | -0.350 | -0.455 | -0.348 | 0.00 | 0.00 | EPS -23.1% · sales - | vs 2023Q1, year-ago quarter · EPS +25.0% · sales - | 6 EPS · 3 sales | Open +2.70% vs SPY +0.32%. Close -2.31% vs SPY +0.13% |
| 2023Q4ended 2023-12-31 | 2024-03-19 16:30 | -0.530 | -0.480 | -0.531 | 0.00 | 0.00 | EPS +10.4% · sales - | vs 2022Q4, year-ago quarter · EPS +71.0% · sales - | 6 EPS · 4 sales | Open +9.38% vs SPY +0.01%. Close +7.89% vs SPY +0.92% |
| 2023Q3ended 2023-09-30 | 2023-11-07 16:30 | -0.490 | -0.353 | -0.493 | 0.00 | 0.00 | EPS +38.7% · sales - | vs 2022Q3, year-ago quarter · EPS +63.3% · sales - | 6 EPS · 4 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-10 16:30 | -0.310 | -0.338 | -0.312 | 0.00 | 0.00 | EPS -8.4% · sales - | vs 2022Q2, year-ago quarter · EPS -13.9% · sales - | 6 EPS · 4 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-04 16:30 | -0.280 | -0.366 | -0.280 | 0.00 | 0.00 | EPS -23.5% · sales - | vs 2022Q1, year-ago quarter · EPS -22.2% · sales - | 5 EPS · 2 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-22 16:30 | -0.310 | -0.360 | -0.306 | 0.00 | 0.00 | EPS -13.9% · sales - | vs 2021Q4, year-ago quarter · EPS +29.2% · sales - | 5 EPS · 2 sales | - |
Annual earnings
2025FY EPS -2.010 missed -1.979, from -1.510 a year earlier. Sales 0.00 matched 0.00, from 0.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.426 | - | - | 281.7 | - |
| 2029FYestimate | - | -2.800 | - | - | 50.04 | - |
| 2028FYestimate | - | -3.255 | - | - | 3.06 | - |
| 2027FYestimate | - | -2.974 | - | - | 0.00 | - |
| 2026FYestimate | - | -2.743 | - | - | 0.00 | - |
| 2025FY | -2.010 | -1.979 | -2.012 | 0.00 | 0.00 | - |
| 2024FY | -1.510 | -1.554 | -1.511 | 0.00 | 0.00 | - |
| 2023FY | -1.620 | -1.577 | -1.619 | 0.00 | 0.00 | - |
| 2022FY | -1.320 | -1.370 | -1.321 | 0.00 | 0.00 | - |
| 2021FY | -1.910 | -0.383 | -0.635 | 0.00 | 0.00 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.00 a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -2.74 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-13 | -2.74 | +0.2% |
| 2026Q4 | E | per share | 2026-11-13 | -0.72 | +0.4% |
| 2026FY | R | per share | 2026-11-13 | -2.71 | +0.1% |
| 2026Q4 | R | per share | 2026-11-13 | -0.77 | +2.1% |
| 2026FY | S | per share | 2026-11-13 | 0.00 | - |
| 2026Q4 | S | per share | 2026-11-13 | 0.00 | - |
| 2026Q3 | E | per share | 2026-10-25 | -0.67 | 0.0% |
| 2026Q3 | R | per share | 2026-10-25 | -0.70 | 0.0% |
| 2026Q3 | S | per share | 2026-08-05 | 0.00 | - |
| 2026Q2 | E | per share | 2026-07-31 | -0.65 | 0.0% |
| 2026Q2 | R | per share | 2026-07-27 | -0.68 | 0.0% |
| 2026Q2 | S | per share | 2026-07-21 | 0.00 | - |
| 2026Q1 | E | per share | 2026-05-12 | -0.59 | 0.0% |
| 2026Q1 | S | per share | 2026-04-13 | 0.00 | - |
| 2026Q1 | R | per share | 2026-04-07 | -0.59 | 0.0% |
| 2025FY | E | per share | 2026-02-23 | -1.98 | -0.3% |
| 2025Q4 | E | per share | 2026-02-23 | -0.53 | -1.3% |
| 2025FY | S | per share | 2026-02-23 | 0.00 | - |
| 2025Q4 | S | per share | 2026-02-23 | 0.00 | - |
| 2025FY | R | per share | 2026-02-12 | -1.98 | +0.5% |
| 2025Q4 | R | per share | 2026-02-12 | -0.54 | +0.5% |
| 2025Q3 | E | per share | 2025-11-02 | -0.50 | 0.0% |
| 2025Q3 | R | per share | 2025-11-02 | -0.48 | 0.0% |
| 2025Q3 | S | per share | 2025-10-08 | 0.00 | - |
| 2025Q2 | E | per share | 2025-08-10 | -0.53 | 0.0% |
| 2025Q2 | R | per share | 2025-08-10 | -0.53 | 0.0% |
| 2025Q2 | S | per share | 2025-05-27 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-30 | -0.49 | -0.9% |
| 2025Q1 | R | per share | 2025-04-30 | -0.47 | -0.4% |
| 2025Q1 | S | per share | 2025-03-28 | 0.00 | - |
| 2024FY | E | per share | 2025-03-26 | -1.54 | 0.0% |
| 2024Q4 | E | per share | 2025-03-26 | -0.46 | 0.0% |
| 2024FY | R | per share | 2025-03-26 | -1.52 | 0.0% |
| 2024Q4 | R | per share | 2025-03-26 | -0.44 | 0.0% |
| 2024FY | S | per share | 2025-03-26 | 0.00 | - |
| 2024Q4 | S | per share | 2025-03-26 | 0.00 | - |
| 2024Q3 | E | per share | 2024-10-25 | -0.40 | +0.1% |
| 2024Q3 | R | per share | 2024-10-25 | -0.39 | +0.1% |
| 2024Q3 | S | per share | 2024-08-14 | 0.00 | - |
| 2024Q2 | E | per share | 2024-07-31 | -0.41 | 0.0% |
| 2024Q2 | R | per share | 2024-07-31 | -0.41 | 0.0% |
| 2024Q2 | S | per share | 2024-05-17 | 0.00 | - |
| 2024Q1 | E | per share | 2024-03-25 | -0.46 | -1.8% |
| 2024Q1 | R | per share | 2024-03-25 | -0.44 | -3.6% |
| 2024Q1 | S | per share | 2024-03-20 | 0.00 | - |
| 2023FY | E | per share | 2024-02-28 | -1.58 | 0.0% |
| 2023FY | R | per share | 2024-02-28 | -1.58 | 0.0% |
| 2023FY | S | per share | 2023-07-06 | 0.00 | - |
Estimate history
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.096 | -0.22 | -0.635 | -1.321 | -1.619 | -1.511 | -2.012 | -2.6324 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 43 | 43 | 41 | 42 | 43 | 51 | 54 | - | 69 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.408 | -0.433 | -0.474 | -0.472 | -0.501 | -0.566 | -0.637 | -0.69 | -0.74 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 53 | 51 | 53 | 53 | 53 | 54 | 59 | 60 | 69 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.54 | 0.55+5.8% | 0.52+48.6% | 0.35+16.7% | 0.30+114.3% | 0.14+180.0% | 0.05+400.0% | 0.01 |
| Gross Profit | -0.54 | -0.55 | -0.52 | -0.35 | -0.30 | -0.14 | -0.05 | -0.01 |
| Selling, General and Administrative Excl. Other | 181.86 | 132.22+27.6% | 103.66+30.2% | 79.59+35.7% | 58.63+124.2% | 26.15+182.7% | 9.25+197.4% | 3.11 |
| Research and Development | 143.46 | 102.38+28.7% | 79.56+28.0% | 62.16+45.5% | 42.71+108.3% | 20.50+186.3% | 7.16+302.2% | 1.78 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -182.40 | -132.76 | -104.18 | -79.94 | -58.93 | -26.29 | -9.30 | -3.12 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.01-98.9% | 0.93 |
| Net Income Before Taxes | -169.82 | -119.95 | -86.48 | -69.13 | -55.33 | -26.29 | -9.34 | -4.07 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -169.82 | -119.95 | -86.48 | -69.13 | -55.33 | -26.29 | -9.34 | -4.07 |
| Net Income From Continuing Operations | -169.82 | -119.95 | -86.48 | -69.13 | -55.33 | -26.29 | -9.34 | -4.07 |
| Net Income | -169.82 | -119.95 | -86.48 | -69.13 | -55.33 | -26.29 | -9.34 | -4.07 |
| EPS (Recurring) per share | -2.46 | -2.01 | -1.51 | -1.62 | -1.32 | -0.63 | -0.22 | -0.08 |
| EPS (Basic, Before Extraordinaries) per share | -2.63 | -2.01 | -1.51 | -1.62 | -1.32 | -0.63 | -0.22 | -0.10 |
| EPS (Diluted) per share | -2.63 | -2.01 | -1.51 | -1.62 | -1.32 | -0.63 | -0.22 | -0.10 |
| EBITDA | -181.86 | -132.22 | -103.66 | -79.59 | -58.63 | -26.15 | -9.25 | -3.11 |
| Non-Operating Income (Expense) | 12.58 | 12.81-27.6% | 17.70+63.7% | 10.81+200.3% | 3.60 | -0.01 | -0.02 | -0.01 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 37.86 | 28.01+22.9% | 22.80+68.5% | 13.53+27.8% | 10.59+266.4% | 2.89+556.8% | 0.44 | - |
| Shares Outstanding million shares | 68.98 | 53.71+5.8% | 50.75+18.0% | 43.02+1.6% | 42.35+2.2% | 41.44-2.6% | 42.540.0% | 42.54 |
| Market Capitalization | 1,363.43 | 1,363.43+85.5% | 734.92+23.6% | 594.57+85.7% | 320.24-44.8% | 579.79+1.0% | 574.02 | - |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.130.0% | 0.140.0% | 0.140.0% | 0.13-7.1% | 0.130.0% | 0.14+7.7% | 0.14+16.7% | 0.14+40.0% |
| Gross Profit | -0.13 | -0.14 | -0.14 | -0.13 | -0.13 | -0.14 | -0.14 | -0.14 |
| Selling, General and Administrative Excl. Other | 54.76+66.9% | 48.87+56.1% | 41.86+32.0% | 36.38+22.9% | 32.81+15.2% | 31.31+33.7% | 31.71+42.8% | 29.60+15.9% |
| Research and Development | 43.01+69.7% | 39.06+61.6% | 33.33+34.3% | 28.05+27.3% | 25.34+12.3% | 24.17+35.3% | 24.82+45.3% | 22.04+7.1% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -54.88 | -49.00 | -42.00 | -36.52 | -32.94 | -31.45 | -31.85 | -29.74 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -51.12 | -45.56 | -39.30 | -33.83 | -29.87 | -28.10 | -28.15 | -25.57 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -51.12 | -45.56 | -39.30 | -33.83 | -29.87 | -28.10 | -28.15 | -25.57 |
| Net Income From Continuing Operations | -51.12 | -45.56 | -39.30 | -33.83 | -29.87 | -28.10 | -28.15 | -25.57 |
| Net Income | -51.12 | -45.56 | -39.30 | -33.83 | -29.87 | -28.10 | -28.15 | -25.57 |
| EPS (Recurring) per share | -0.74 | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 |
| EPS (Basic, Before Extraordinaries) per share | -0.74 | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 |
| EPS (Diluted) per share | -0.74 | -0.69 | -0.64 | -0.57 | -0.50 | -0.47 | -0.47 | -0.43 |
| EBITDA | -54.76 | -48.87 | -41.86 | -36.38 | -32.81 | -31.31 | -31.71 | -29.60 |
| Non-Operating Income (Expense) | 3.76+22.1% | 3.44+2.7% | 2.69-27.3% | 2.68-35.7% | 3.08-32.9% | 3.35-30.6% | 3.70-10.4% | 4.17+48.9% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 12.16+60.4% | 10.23+60.3% | 7.85+22.3% | 7.63+13.9% | 7.58+0.1% | 6.38+44.7% | 6.42+55.8% | 6.70+59.9% |
| Shares Outstanding million shares | 68.98+29.4% | 59.66+12.1% | 59.47+12.0% | 53.71+5.8% | 53.32+0.9% | 53.23+0.9% | 53.09+1.2% | 50.75+18.0% |
| Market Capitalization | 1,363.43+83.1% | 1,899.46+273.2% | 2,056.96+335.8% | 1,401.74+90.7% | 744.74-39.9% | 508.91-39.3% | 471.97-33.1% | 734.92+23.6% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 256.00-25.0% | 341.44+67.8% | 203.47-19.0% | 251.21-16.9% | 302.18+1885.4% | 15.22+13736.4% | 0.11 |
| Short Term Receivables | 1.90-5.0% | 2.00+185.7% | 0.70 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 7.55+87.8% | 4.02-46.4% | 7.50+23.4% | 6.08+223.4% | 1.88+3033.3% | 0.06+200.0% | 0.02 |
| Total Current Assets | 265.45-23.6% | 347.46+64.2% | 211.67-17.7% | 257.29-15.4% | 304.06+1889.9% | 15.28+11653.8% | 0.13 |
| Net Property, Plant & Equipment | 6.89-10.8% | 7.72-5.3% | 8.15+130.2% | 3.54+69.4% | 2.09+344.7% | 0.47+67.9% | 0.28 |
| Total Investments and Advances | 1.000.0% | 1.000.0% | 1.000.0% | 1.00+316.7% | 0.240.0% | 0.24 | 0.00 |
| Intangible Assets | - | - | - | - | - | 0.00 | - |
| Deferred Tax Assets | 1.44-6.5% | 1.54 | - | - | 0.26 | - | - |
| Other Assets | 9.27+25.6% | 7.38+46.7% | 5.03+15.6% | 4.35+1303.2% | 0.31+1450.0% | 0.02-83.3% | 0.12 |
| Total Assets | 284.05-22.2% | 365.10+61.6% | 225.86-15.1% | 266.18-13.3% | 306.96+1817.3% | 16.01+2920.8% | 0.53 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.47+14.6% | 0.41+46.4% | 0.28+100.0% | 0.14-30.0% | 0.20+42.9% | 0.140.0% | 0.14 |
| Accounts Payable | 1.18+100.0% | 0.59-87.3% | 4.66+305.2% | 1.15+91.7% | 0.60-9.1% | 0.66+100.0% | 0.33 |
| Other Current Liabilities | 16.44+21.0% | 13.59+30.8% | 10.39+135.1% | 4.42+57.3% | 2.81+167.6% | 1.05-77.6% | 4.69 |
| Total Current Liabilities | 18.09+24.0% | 14.59-4.8% | 15.33+168.9% | 5.70+57.5% | 3.62+94.6% | 1.86-64.0% | 5.16 |
| Long Term Debt | 5.34-8.1% | 5.81-6.6% | 6.22+150.8% | 2.48+153.1% | 0.98-96.5% | 27.65+25036.4% | 0.11 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 1.44-6.5% | 1.54 | - | - | 0.26 | - | - |
| Other Liabilities | 0.00 | 0.00-100.0% | 0.05-70.6% | 0.17-54.1% | 0.37+164.3% | 0.14 | 0.00 |
| Total Liabilities | 24.87+13.3% | 21.95+1.7% | 21.59+158.6% | 8.35+59.7% | 5.23-82.4% | 29.65+462.6% | 5.27 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 259.18-24.5% | 343.15+68.0% | 204.26-20.8% | 257.83-14.6% | 301.74 | -13.64 | -4.74 |
| Total Shareholders Equity | 259.18-24.5% | 343.15+68.0% | 204.26-20.8% | 257.83-14.6% | 301.74 | -13.64 | -4.74 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 259.18-24.5% | 343.15+68.0% | 204.26-20.8% | 257.83-14.6% | 301.74 | -13.64 | -4.74 |
| Total Liabilities & Stockholders Equity | 284.05-22.2% | 365.10+61.6% | 225.86-15.1% | 266.18-13.3% | 306.96+1817.3% | 16.01+2920.8% | 0.53 |
| Book Value Per Share per share | 4.83-28.6% | 6.76+42.3% | 4.75-22.0% | 6.09-16.3% | 7.28 | -0.32 | -0.11 |
| Tangible Book Value Per Share per share | 4.83-28.6% | 6.76+42.3% | 4.75-22.0% | 6.09-16.3% | 7.28 | -0.32 | -0.11 |
| Full-Time Employees people | 87+45.0% | 60+22.4% | 49+28.9% | 38+52.0% | 25 | - | - |
| Price to Book Ratio ratio | 1.97 | 2.03 | 2.68 | 1.20 | 1.93 | 1.85 | - |
| Return on Assets % | -36.96 | -29.27 | -28.10 | -19.31 | -16.28 | -112.90 | - |
| Return on Equity % | -39.83 | -31.60 | -29.92 | -19.77 | -18.25 | - | - |
| Return on Invested Capital % | -45.35 | -24.78 | -32.85 | -21.25 | -8.69 | -66.62 | - |
| Quick Ratio ratio | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 |
| Current Ratio ratio | 14.67 | 23.81 | 13.80 | 45.13 | 84.09 | 8.22 | 0.02 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -169.82 | -119.95 | -86.48 | -69.13 | -55.33 | -26.29 | -9.34 | -4.07 |
| Depreciation | 0.54 | 0.55+5.8% | 0.52+48.6% | 0.35+16.7% | 0.30+114.3% | 0.14+180.0% | 0.05+400.0% | 0.01 |
| Other Funds (Non Cash) | 37.37 | 25.89+53.0% | 16.92+37.8% | 12.28+16.0% | 10.59+266.4% | 2.89+528.3% | 0.46-50.5% | 0.93 |
| Funds from Operations | -131.91 | -93.51 | -69.05 | -56.50 | -44.44 | -23.26 | -8.83 | -3.12 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 12.43 | -1.63 | -0.73-111.5% | 6.36 | -5.85 | -0.48-144.9% | 1.07+109.8% | 0.51 |
| Cash from Operating Activities | -119.48 | -95.14 | -69.77 | -50.14 | -50.28 | -23.75 | -7.76 | -2.62 |
| Capital Expenditures | -0.30 | -0.14 | -0.66 | -0.77 | -0.56 | -0.66 | -0.31 | -0.02 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.02 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -32.79 | 72.60 | -97.74 | -143.84 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -212.38 | -101.25 | -263.62 | -143.84 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 179.59 | 173.86+4.8% | 165.88 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -33.09 | 72.46 | -98.40 | -144.60 | -0.56 | -0.65 | -0.31 | -0.02 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 546.64 | 8.10-96.0% | 202.14+13026.0% | 1.54+144.4% | 0.63-99.8% | 311.38+1227.8% | 23.45+13694.1% | 0.17 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 546.64 | 8.10-96.0% | 202.14+13026.0% | 1.54+144.4% | 0.63-99.8% | 311.38+1227.8% | 23.45+13694.1% | 0.17 |
| Proceedsfrom Stock Options | 165.16 | 0.00-100.0% | 199.58 | 0.00 | 0.00-100.0% | 310.84+1233.5% | 23.31+13611.8% | 0.17 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -0.02 | -0.01 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.03 | 0.00 | 0.00 |
| Cash from Financing Activities | 546.64 | 8.10-96.0% | 202.14+13026.0% | 1.54+144.4% | 0.63-99.8% | 311.35+1228.9% | 23.43+14543.8% | 0.16 |
| Net Change in Cash | 394.06 | -14.58-142.9% | 33.96 | -193.21 | -50.21-117.5% | 286.96+1768.2% | 15.36 | -2.48 |
| Free Cash Flow | -119.78 | -95.28 | -70.44 | -50.91 | -50.84 | -24.41 | -8.07 | -2.64 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 700.66+154.9% | 354.06+19.5% | 383.47+20.2% | 256.00-25.0% | 274.92-23.7% | 296.27-20.7% | 318.94-16.6% | 341.44+67.8% |
| Short Term Receivables | 2.200.0% | 2.50+47.1% | 2.70+50.0% | 1.90-5.0% | 2.20+15.8% | 1.70-10.5% | 1.80+20.0% | 2.00+185.7% |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 8.75+113.9% | 10.41+149.0% | 8.45+121.2% | 7.55+87.8% | 4.09+14.2% | 4.18+45.1% | 3.82-44.0% | 4.02-46.4% |
| Total Current Assets | 711.62+153.0% | 366.97+21.5% | 394.61+21.6% | 265.45-23.6% | 281.22-23.1% | 302.15-20.2% | 324.57-16.9% | 347.46+64.2% |
| Net Property, Plant & Equipment | 6.26-11.1% | 6.48-10.5% | 6.66-10.8% | 6.89-10.8% | 7.04-11.7% | 7.24-11.6% | 7.47-6.7% | 7.72-5.3% |
| Total Investments and Advances | 0.88-12.0% | 0.88-12.0% | 0.88-12.0% | 1.000.0% | 1.000.0% | 1.000.0% | 1.000.0% | 1.000.0% |
| Deferred Tax Assets | - | - | - | 1.44-6.5% | - | - | - | 1.54 |
| Other Assets | 8.76-30.4% | 9.03-18.7% | 9.88-5.4% | 9.27+25.6% | 12.59+109.5% | 11.11+136.9% | 10.44+110.5% | 7.38+46.7% |
| Total Assets | 727.53+141.0% | 383.36+19.2% | 412.04+20.0% | 284.05-22.2% | 301.85-20.7% | 321.50-18.1% | 343.48-15.1% | 365.10+61.6% |
| Short Term Debt Incl. Current Port. of LT Debt | 0.52+13.0% | 0.50+13.6% | 0.49+14.0% | 0.47+14.6% | 0.46+15.0% | 0.44+15.8% | 0.43+16.2% | 0.41+46.4% |
| Accounts Payable | 3.30+65.8% | 2.33+3.6% | 3.64+45.6% | 1.18+100.0% | 1.99+70.1% | 2.25+42.4% | 2.50-13.2% | 0.59-87.3% |
| Other Current Liabilities | 25.92+93.0% | 21.78+96.6% | 15.13+33.7% | 16.44+21.0% | 13.43+24.2% | 11.08+31.6% | 11.32+106.9% | 13.59+30.8% |
| Total Current Liabilities | 29.74+87.3% | 24.62+78.8% | 19.26+35.2% | 18.09+24.0% | 15.88+28.4% | 13.77+32.7% | 14.25+63.4% | 14.59-4.8% |
| Long Term Debt | 4.94-9.5% | 5.08-9.0% | 5.21-8.6% | 5.34-8.1% | 5.46-7.8% | 5.58-7.3% | 5.70-6.9% | 5.81-6.6% |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | 1.44-6.5% | - | - | - | 1.54 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% |
| Total Liabilities | 34.68+62.5% | 29.70+53.5% | 24.46+22.7% | 24.87+13.3% | 21.34+16.6% | 19.35+17.8% | 19.94+34.2% | 21.95+1.7% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 692.84+147.0% | 353.66+17.0% | 387.57+19.8% | 259.18-24.5% | 280.51-22.6% | 302.15-19.6% | 323.53-17.0% | 343.15+68.0% |
| Total Shareholders Equity | 692.84+147.0% | 353.66+17.0% | 387.57+19.8% | 259.18-24.5% | 280.51-22.6% | 302.15-19.6% | 323.53-17.0% | 343.15+68.0% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 692.84+147.0% | 353.66+17.0% | 387.57+19.8% | 259.18-24.5% | 280.51-22.6% | 302.15-19.6% | 323.53-17.0% | 343.15+68.0% |
| Total Liabilities & Stockholders Equity | 727.53+141.0% | 383.36+19.2% | 412.04+20.0% | 284.05-22.2% | 301.85-20.7% | 321.50-18.1% | 343.48-15.1% | 365.10+61.6% |
| Book Value Per Share per share | 10.04+90.9% | 5.93+4.4% | 6.52+7.1% | 4.83-28.6% | 5.26-23.2% | 5.68-20.3% | 6.09-18.0% | 6.76+42.3% |
| Tangible Book Value Per Share per share | 10.04+90.9% | 5.93+4.4% | 6.52+7.1% | 4.83-28.6% | 5.26-23.2% | 5.68-20.3% | 6.09-18.0% | 6.76+42.3% |
| Full-Time Employees people | - | - | - | 87+45.0% | - | - | - | 60+22.4% |
| Price to Book Ratio ratio | 1.97 | 4.90 | 7.94 | 5.00 | 2.46 | 1.57 | 1.38 | 2.03 |
| Return on Assets % | -32.99 | -42.15 | -34.71 | -36.96 | -32.73 | -29.65 | -25.78 | -29.27 |
| Return on Equity % | -34.89 | -45.31 | -36.87 | -39.83 | -34.75 | -31.21 | -27.04 | -31.60 |
| Return on Invested Capital % | -7.33 | -12.70 | -10.01 | -12.79 | -10.44 | -9.13 | -8.55 | -7.33 |
| Quick Ratio ratio | 23.93 | 14.91 | 20.49 | 14.67 | 17.71 | 21.94 | 22.78 | 23.81 |
| Current Ratio ratio | 23.93 | 14.91 | 20.49 | 14.67 | 17.71 | 21.94 | 22.78 | 23.81 |
Cash flow, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -51.12 | -45.56 | -39.30 | -33.83 | -29.87 | -28.10 | -28.15 | -25.57 |
| Depreciation | 0.130.0% | 0.140.0% | 0.140.0% | 0.13-7.1% | 0.130.0% | 0.14+7.7% | 0.14+16.7% | 0.14+40.0% |
| Other Funds (Non Cash) | 12.02+67.9% | 10.03+76.9% | 7.82+40.6% | 7.50+35.9% | 7.16+19.9% | 5.67+123.2% | 5.56+92.4% | 5.52+87.8% |
| Funds from Operations | -38.97 | -35.39 | -31.34 | -26.20 | -22.58 | -22.29 | -22.45 | -19.91 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 6.76+3280.0% | 4.32 | -1.23 | 2.58+706.3% | 0.20+900.0% | -1.39-124.1% | -3.01 | 0.32-94.9% |
| Cash from Operating Activities | -32.21 | -31.08 | -32.57 | -23.62 | -22.38 | -23.68 | -25.46 | -19.59 |
| Capital Expenditures | -0.09 | -0.07 | -0.09 | -0.06 | -0.04 | -0.03 | -0.01 | -0.01 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 35.01 | 17.92-14.3% | -120.16-475.0% | 34.43+394.7% | -14.77-168.3% | 20.90 | 32.04+75.9% | 6.96 |
| Purchase of Investments | -18.99 | -22.08 | -162.21 | -9.11 | -65.17 | -20.11 | -6.87 | -38.04 |
| Sale Or Maturity of Investments | 54.00+7.1% | 40.00-2.4% | 42.05+8.1% | 43.54-3.2% | 50.41-13.1% | 41.00+24.7% | 38.91+29.7% | 45.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 34.92 | 17.85-14.5% | -120.24-475.4% | 34.38+394.0% | -14.81-168.7% | 20.87 | 32.03+77.3% | 6.96 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 379.47+58280.0% | 2.10+262.1% | 160.38+7223.3% | 4.68+559.2% | 0.65-12.2% | 0.58+56.8% | 2.19-98.9% | 0.71+121.9% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 379.47+58280.0% | 2.10+262.1% | 160.38+7223.3% | 4.68+559.2% | 0.65-12.2% | 0.58+56.8% | 2.19-98.9% | 0.71+121.9% |
| Proceedsfrom Stock Options | 17.31 | 0.00 | 147.85 | 0.00-100.0% | 0.00 | 0.00 | 0.00 | 200.00 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 379.47+58280.0% | 2.10+262.1% | 160.38+7223.3% | 4.68+559.2% | 0.65-12.2% | 0.58+56.8% | 2.19-98.9% | 0.71+121.9% |
| Net Change in Cash | 382.18 | -11.12 | 7.57-13.6% | 15.44 | -36.54-930.5% | -2.23 | 8.76-95.5% | -11.93 |
| Free Cash Flow | -32.30 | -31.14 | -32.66 | -23.68 | -22.42 | -23.71 | -25.47 | -19.60 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 21.63% | 9.9M | 45.8M | 867.79K |
| 2026-10-15 | 20.75% | 9.5M | 45.8M | 842.49K |
| 2026-09-30 | 20.57% | 9.4M | 45.8M | 848.87K |
| 2026-09-15 | 21.58% | 9.9M | 45.8M | 877.12K |
| 2026-08-31 | 21.59% | 9.4M | 43.7M | 770.00K |
| 2026-08-14 | 22.16% | 9.7M | 43.7M | 839.20K |
| 2026-07-31 | 20.86% | 9.2M | 44.3M | 811.40K |
| 2026-07-15 | 22.48% | 9.9M | 44.2M | 930.31K |
| 2026-06-30 | 26.99% | 11.9M | 44.2M | 997.73K |
| 2026-06-15 | 22.33% | 9.9M | 44.2M | 959.35K |
| 2026-05-29 | 21.01% | 9.3M | 44.2M | 1.05M |
| 2026-05-15 | 18.26% | 8.1M | 44.2M | 1.07M |
| 2026-04-30 | 19.49% | 7.7M | 39.6M | 1.09M |
| 2026-04-15 | 20.86% | 7.7M | 37.0M | 1.03M |
| 2026-03-31 | 22.47% | 8.3M | 36.8M | 961.00K |
| 2026-03-13 | 18.63% | 6.9M | 36.8M | 857.61K |
| 2026-02-27 | 15.41% | 5.7M | 36.8M | 657.34K |
| 2026-02-13 | 14.09% | 5.1M | 36.5M | 642.24K |
| 2026-01-30 | 13.75% | 5.0M | 36.5M | 554.78K |
| 2026-01-15 | 13.92% | 5.1M | 36.5M | 475.39K |
Option chain
Expiry 2026-11-20 · underlying 19.41, quoted 13 Nov 07:14 ET · ATM 20.00
Option quotes 9 Nov 14:40 ET. A date on a row is older than the last session (12 Nov). 36 rows.
Implied move 25.24% into expiry (call 2.450 + put 2.450 = 4.900 on 19.41)
Put/call open interest 0.83 (223 puts / 270 calls) · Put/call volume — no calls
IV change is points against the prior close.
| Type | Strike | Money | Bid | Ask | Last | Chg | IV | Open int | Volume | Last size | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| call 1 Jan | 7.50 | ITM | 10.10 | 15.00 | 0.00 | 0.00 | 1089.5% -38.9 | 0 | 0 | 0 | 0.921 | -0.307 | 0.004 |
| put 1 Jan | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 1121.7% 0.0 | 0 | 0 | 0 | -0.075 | -0.299 | 0.004 | |
| call 1 Jan | 10.00 | ITM | 7.60 | 12.50 | 0.00 | 0.00 | 820.3% -28.9 | 0 | 0 | 0 | 0.879 | -0.316 | 0.006 |
| put 16 Oct | OTM | 0.00 | 4.90 | 0.10 | 0.00 | 848.7% 0.0 | 1 | 0 | 0 | -0.115 | -0.310 | 0.006 | |
| call 1 Jan | 12.50 | ITM | 5.10 | 9.90 | 0.00 | 0.00 | 588.1% -67.3 | 0 | 0 | 0 | 0.833 | -0.306 | 0.007 |
| put 16 Oct | OTM | 0.00 | 4.90 | 0.15 | 0.00 | 657.5% 0.0 | 1 | 0 | 0 | -0.160 | -0.301 | 0.007 | |
| call 23 Sep | 15.00 | ITM | 2.65 | 7.50 | 9.31 | 0.00 | 479.0% -19.8 | 3 | 0 | 0 | 0.771 | -0.280 | 0.009 |
| put 3 Nov | OTM | 0.00 | 4.90 | 0.45 | 0.00 | 498.8% 0.0 | 14 | 0 | 0 | -0.229 | -0.278 | 0.009 | |
| call 21 Oct | 17.50 | ITM | 0.10 | 4.90 | 3.50 | 0.00 | 339.2% -26.9 | 8 | 0 | 0 | 0.690 | -0.240 | 0.010 |
| put 30 Oct | OTM | 0.00 | 2.90 | 0.25 | 0.00 | 378.0% 0.0 | 3 | 0 | 0 | -0.273 | -0.232 | 0.011 | |
| call 21 Oct | 20.00 | ATM | 0.00 | 4.90 | 1.80 | 0.00 | 438.8% +8.9 | 22 | 0 | 0 | 0.617 | -0.304 | 0.011 |
| put 30 Oct | ATM | 0.00 | 4.90 | 1.20 | 0.00 | 418.7% -11.2 | 198 | 0 | 0 | -0.383 | -0.302 | 0.011 | |
| call 9 Nov | 22.50 | OTM | 0.00 | 4.90 | 1.00 | 0.00 | 477.9% +0.2 | 113 | 0 | 0 | 0.588 | -0.350 | 0.012 |
| put 14 Sep | ITM | 0.50 | 4.90 | 2.00 | 0.00 | 274.9% -236.9 | 4 | 0 | 0 | -0.420 | -0.368 | 0.011 | |
| call 20 Oct | 25.00 | OTM | 0.00 | 4.90 | 0.10 | 0.00 | 537.1% 0.0 | 18 | 0 | 0 | 0.559 | -0.399 | 0.012 |
| put 25 Sep | ITM | 2.55 | 7.40 | 4.00 | 0.00 | 338.9% -208.6 | 1 | 0 | 0 | -0.445 | -0.401 | 0.012 | |
| call 30 Sep | 27.50 | OTM | 0.00 | 4.90 | 0.45 | 0.00 | 586.3% 0.0 | 2 | 0 | 0 | 0.539 | -0.438 | 0.012 |
| put 10 Sep | ITM | 5.00 | 9.50 | 5.85 | 0.00 | 344.3% -274.6 | 1 | 0 | 0 | -0.464 | -0.452 | 0.012 | |
| call 3 Nov | 30.00 | OTM | 0.00 | 1.75 | 0.20 | 0.00 | 377.4% 0.0 | 42 | 0 | 0 | 0.320 | -0.250 | 0.010 |
| put 30 Sep | ITM | 7.50 | 12.40 | 8.08 | 0.00 | 421.9% +41.2 | 0 | 0 | 0 | -0.680 | -0.249 | 0.010 | |
| call 25 Sep | 32.50 | OTM | 0.00 | 4.90 | 0.35 | 0.00 | 411.6% 0.0 | 1 | 0 | 0 | 0.327 | -0.280 | 0.011 |
| put 1 Jan | ITM | 10.00 | 14.90 | 0.00 | 0.00 | 457.4% +42.2 | 0 | 0 | 0 | -0.696 | -0.265 | 0.010 | |
| call 25 Sep | 35.00 | OTM | 0.00 | 5.00 | 0.15 | 0.00 | 297.1% 0.0 | 24 | 0 | 0 | 0.137 | -0.121 | 0.006 |
| put 8 Jun | ITM | 12.50 | 17.40 | 13.00 | 0.00 | 488.8% +191.7 | 0 | 0 | 0 | -0.863 | -0.117 | 0.006 | |
| call 1 Jan | 37.50 | OTM | 0.00 | 4.90 | 0.00 | 0.00 | 301.4% 0.0 | 0 | 0 | 0 | 0.130 | -0.120 | 0.006 |
| put 1 Jan | ITM | 15.00 | 19.90 | 0.00 | 0.00 | 517.1% +196.4 | 0 | 0 | 0 | -0.870 | -0.121 | 0.006 | |
| call 11 Sep | 40.00 | OTM | 0.00 | 4.90 | 0.50 | 0.00 | 322.8% 0.0 | 23 | 0 | 0 | 0.124 | -0.125 | 0.006 |
| put 15 May | ITM | 17.50 | 22.40 | 11.80 | 0.00 | 542.7% +200.5 | 0 | 0 | 0 | -0.876 | -0.125 | 0.006 | |
| call 11 Sep | 42.50 | OTM | 0.00 | 4.90 | 0.45 | 0.00 | 342.4% 0.0 | 1 | 0 | 0 | 0.119 | -0.128 | 0.006 |
| put 1 Jan | ITM | 20.00 | 24.90 | 0.00 | 0.00 | 566.2% +204.2 | 0 | 0 | 0 | -0.880 | -0.129 | 0.006 | |
| call 11 Sep | 45.00 | OTM | 0.00 | 4.90 | 0.40 | 0.00 | 360.5% 0.0 | 6 | 0 | 0 | 0.115 | -0.132 | 0.006 |
| put 1 Jan | ITM | 22.50 | 27.40 | 0.00 | 0.00 | 587.8% +207.6 | 0 | 0 | 0 | -0.884 | -0.132 | 0.006 | |
| call 11 Sep | 50.00 | OTM | 0.00 | 4.90 | 0.40 | 0.00 | 392.9% 0.0 | 6 | 0 | 0 | 0.109 | -0.138 | 0.006 |
| put 16 Apr | ITM | 27.50 | 32.40 | 19.76 | 0.00 | 626.6% +213.5 | 0 | 0 | 0 | -0.891 | -0.137 | 0.005 | |
| call 11 Sep | 55.00 | OTM | 0.00 | 4.90 | 0.40 | 0.00 | 421.4% 0.0 | 1 | 0 | 0 | 0.104 | -0.143 | 0.005 |
| put 1 Jan | ITM | 32.50 | 37.40 | 0.00 | 0.00 | 660.5% +218.7 | 0 | 0 | 0 | -0.896 | -0.142 | 0.005 |
Latest SEC filings
30 of 428AllAll annual, quarterly, and current reportsInsider equity awards, transactions, and ownership (Section 16 Reports)Beneficial ownership reportsExempt offeringsRegistration statements and prospectusesFiling review correspondenceSEC orders and noticesProxy materialsTender offers and going private transactionsTrust indenture filings
10-Q filed 2026-11-10, period ended 2026-09-30. 10-K filed 2026-03-02, period ended 2025-12-31. TYRA on EDGAR
page 1 of 15Next →
| Filed | Form | Description | Period | Document |
|---|---|---|---|---|
| 2026-11-10 | 10-Q | All annual, quarterly, and current reports | 2026-09-30 | 0001193125-26-454481 index |
| 2026-11-10 | 8-K | All annual, quarterly, and current reports | 2026-11-10 | 0001193125-26-454474 index |
| 2026-10-27 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0002012383-26-003856 index |
| 2026-09-21 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0000921895-26-002613 index |
| 2026-09-17 | SCHEDULE 13D/A | Beneficial ownership reports | no report period | 0001346824-26-000237 index |
| 2026-09-17 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-15 · transaction | 0001231919-26-001194 index |
| 2026-09-17 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-15 · transaction | 0001193125-26-394738 index |
| 2026-09-17 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-15 · transaction | 0001193125-26-394734 index |
| 2026-09-17 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-15 · transaction | 0001193125-26-394731 index |
| 2026-09-17 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0001104659-26-108569 index |
| 2026-09-15 | 8-K | All annual, quarterly, and current reports | 2026-09-14 | 0001193125-26-390951 index |
| 2026-09-15 | 424B5 | Registration statements and prospectuses | no report period | 0001193125-26-390947 index |
| 2026-09-14 | FWP | Registration statements and prospectuses | no report period | 0001193125-26-389801 index |
| 2026-09-14 | S-3ASR | Registration statements and prospectuses | no report period | 0001193125-26-389752 index |
| 2026-09-11 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-09-09 · transaction | 0001193125-26-389333 index |
| 2026-09-09 | 8-K | All annual, quarterly, and current reports | 2026-09-09 | 0001193125-26-385886 index |
| 2026-08-14 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0001804218-26-000003 index |
| 2026-08-14 | SCHEDULE 13G/A | Beneficial ownership reports | no report period | 0000908834-26-000427 index |
| 2026-08-04 | 424B5 | Registration statements and prospectuses | no report period | 0001193125-26-333055 index |
| 2026-08-04 | 10-Q | All annual, quarterly, and current reports | 2026-06-30 | 0001193125-26-332995 index |
| 2026-08-04 | 8-K | All annual, quarterly, and current reports | 2026-08-04 | 0001193125-26-332752 index |
| 2026-07-30 | SCHEDULE 13G | Beneficial ownership reports | no report period | 0002012383-26-003114 index |
| 2026-06-26 | 144 | no category | no report period | 0001628280-26-045813 index |
| 2026-06-02 | 8-K | All annual, quarterly, and current reports | 2026-05-28 | 0001193125-26-253435 index |
| 2026-06-01 | 144 | no category | no report period | 0001628280-26-039506 index |
| 2026-06-01 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-28 · transaction | 0001231919-26-000590 index |
| 2026-06-01 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-28 · transaction | 0001193125-26-251539 index |
| 2026-06-01 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-28 · transaction | 0001193125-26-251538 index |
| 2026-06-01 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-28 · transaction | 0001193125-26-251537 index |
| 2026-06-01 | 4 | Insider equity awards, transactions, and ownership (Section 16 Reports) | 2026-05-28 · transaction | 0001193125-26-251536 index |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 20.00K | 1 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 528.51K | 1 |
| 2026-02 | 0 | 0 | 262.96K | 1 |
| 2026-01 | 0 | 0 | 228.19K | 1 |
| 2025-12 | 0 | 0 | 431.16K | 2 |
| 2025-11 | 0 | 0 | 9.14M | 6 |
Institutional holders
| Manager | % owned |
|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 20.51% |
| FMR LLC | 17.66% |
| Jupiter Topco LLC | 7.32% |
| Alta Partners Management Company, L.P. | 6.43% |
| Nextech Invest Ltd. | 5.98% |
| Siren, L.L.C. | 5.69% |
| TCG Crossover Management, LLC | 5.46% |
| BlackRock, Inc. | 5.10% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 4.68% |
| STATE STREET CORP | 3.35% |
Funds
| Fund | % owned |
|---|---|
| Fidelity OTC Portfolio | 5.54% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2.34% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.91% |
| iShares Russell 2000 ETF | 1.59% |
| T. Rowe Price New Horizons Fund, Inc. | 1.33% |
| Fidelity Advisor Equity Growth Fund | 1.14% |
| VIP Growth Portfolio | 1.06% |
| T. Rowe Price Integrated U.S. Small-Cap Growth Equity Fund | 0.94% |
| Hood River Small-Cap Growth Fund | 0.83% |
| Fidelity Small Cap Index Fund | 0.68% |
OakChart. TYRA. Cached 15 minutes. Terms